Filing Details
- Accession Number:
- 0001217234-23-000028
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-02-03 21:47:01
- Reporting Period:
- 2023-02-01
- Accepted Time:
- 2023-02-03 21:47:01
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1217234 | Caredx Inc. | CDNA | Services-Medical Laboratories (8071) | 943316839 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1688485 | Reginald Seeto | C/O Caredx, Inc. 8000 Marina Boulevard Brisbane CA 94005 | See Remarks | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-02-01 | 302,000 | $0.00 | 569,152 | No | 4 | A | Direct | |
| Common Stock | Acquisiton | 2023-02-01 | 11,800 | $0.00 | 580,952 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2023-02-01 | 2,330 | $15.66 | 578,622 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-02 | 2,316 | $17.07 | 576,306 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 503 | $17.50 | 575,803 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2023-02-02 | 7,244 | $17.61 | 568,559 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-03 | 1,228 | $16.54 | 567,331 | No | 4 | F | Direct | |
| Common Stock | Disposition | 2023-02-03 | 1,228 | $16.54 | 566,103 | No | 4 | F | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | A | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct | |
| No | 4 | F | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2023-02-01 | 156,000 | $0.00 | 156,000 | $15.66 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 156,000 | 2033-02-01 | No | 4 | A | Direct |
Footnotes
- The reported securities are represented by restricted stock units, 1/4th of which shall vest on February 1, 2024 and 1/4th of which shall vest on each anniversary thereafter.
- Includes 177 shares acquired on January 2, 2023 pursuant to the Issuer's 2014 Employee Stock Purchase Plan.
- The reported securities were subject to a performance restricted stock unit award that was initially granted on February 3, 2021 for a two-year performance period over calendar years 2021 and 2022, which performance was assessed and finalized effective February 1, 2023. 50.00% of the reported securities vested on February 1, 2023 and 50% of the reported securities will vest on December 31, 2023, subject to the Reporting Person's continued service with the Issuer.
- These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.
- This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $17.34, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.44 to $17.61, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price.
- 1/4th of the shares subject to the option shall vest on February 2, 2024 and 1/48th of the shares subject to the option shall vest monthly thereafter.
Billionaire Hedge Funds
